Soleno Therapeutics posts Q3 2025 results update

Soleno Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Soleno Therapeutics, Inc. furnished an update on its business by announcing financial results for the quarter ended September 30, 2025. The company reported these quarterly results through a press release dated November 4, 2025, which is attached as Exhibit 99.1 to this report and incorporated by reference.

The information is provided under the “Results of Operations and Financial Condition” section of the rules governing current reports and is designated as furnished rather than filed. This means it is not subject to certain liability provisions and is not automatically included in other securities law filings unless specifically referenced.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Soleno Therapeutics (SLNO) disclose in this 8-K filing?

Soleno Therapeutics disclosed that it issued a press release with financial results for the quarter ended September 30, 2025, and furnished that release as Exhibit 99.1.

Which period do Soleno Therapeutics' latest results in this 8-K cover?

The press release furnished in the filing contains financial results for the quarter ended September 30, 2025.

How did Soleno Therapeutics provide its Q3 2025 financial results?

The company provided its Q3 2025 financial results through a press release dated November 4, 2025, which is attached as Exhibit 99.1 and incorporated by reference.

Is the Soleno Therapeutics earnings information considered filed with the SEC?

No. The company states that the information is furnished, not filed, so it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.

What exhibits are included in this Soleno Therapeutics 8-K?

The filing lists Exhibit 99.1, the press release with quarterly financial results, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

Who signed Soleno Therapeutics’ 8-K for the Q3 2025 results?

The report was signed on behalf of Soleno Therapeutics, Inc. by Anish Bhatnagar, Chief Executive Officer, on November 4, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/04/2025 - 04:05 PM EST Learn about SEC filing dates

SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-11-04 2025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 4, 2025

SOLENO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36593		77-0523891
(State or other jurisdiction of incorporation)		(Commission File No.)		(IRS Employer Identification Number)

100 Marine Parkway, Suite 400

Redwood City, CA 94065

(Address of principal executive offices)

(650) 213-8444

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbols		Name of each exchange on which registered
Common Stock, $0.001 par value		SLNO		NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 Results of Operations and Financial Conditions

On November 4, 2025, Soleno Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 Financial Statements and Exhibits

(d)             Exhibits

Exhibit No.		Description
99.1		Press release issued by Soleno Therapeutics, Inc. dated November 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				SOLENO THERAPEUTICS, INC.
Date: November 4, 2025
				By:		/s/ Anish Bhatnagar
						Anish Bhatnagar
						Chief Executive Officer